Jaka jest cena za Sesen Bio, Inc. (SESN)

Cena za Sesen Bio, Inc. (SESN) wynosi $0.6288

Jaka jest kapitalizacja rynkowa dla Sesen Bio, Inc. (SESN)

Kapitalizacja rynkowa dla Sesen Bio, Inc. (SESN) wynosi $6.00M

Sesen Bio, Inc. (SESN) Wskaźnik C/P

Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Rok	Wskaźnik P/S	Zmień
Za mało danych dla podanych dat.

Rok

Wskaźnik P/S

Zmień

Za mało danych dla podanych dat.

Firma	Wskaźnik P/S	Różnica wskaźnika P/S	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.74	-	BE

Firma

Wskaźnik P/S

Różnica wskaźnika P/S

Kraj